Deadline: 15-Feb-24
The Department of Health and Human Services and National Institutes of Health is pleased to launch the High Priority HIV and Substance Use Research to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD).
This FOA is designed to attract exceptionally talented investigators to conduct innovative, potentially groundbreaking investigations at the intersection of HIV and substance use. Examples of relevant studies include but are not limited to:
- Innovative strategies and interventions at the individual, provider, and community level to reduce stigma that impedes the provision and utilization of services for substance use and HIV prevention and / or care.
- Innovative approaches to assess and / or address social determinants related to substance use and HIV with attention to longstanding structural issues such as racism and community resources.
- Studies developing and testing the use of media and communication campaigns to address stigma and build demand for evidence-based practices addressing substance use and HIV prevention and / or treatment.
- Innovative approaches to model HIV risk and predict future hotspots in the context of changing drug use epidemics (domestic or international)
- Novel modeling approaches to estimate population-level effects of epidemic dynamics and / or intervention strategies on HIV incidence and HIV clinical outcomes.
- Novel biomedical, behavioral and / or integrated strategies to improve prevention and treatment outcomes for people living with or at risk for HIV and SUDs.
- Implementation research that develops and tests strategies to increase the availability, uptake, and sustainability of evidence-based HIV and substance use prevention and / or treatment interventions, emphasizing jurisdictions with high HIV / substance use burden.
- Demonstrations of how to aggregate data from different settings to understand population needs, resources and infrastructure within jurisdictions to promote effective community-based approaches to address HIV and substance use prevention and / or treatment.
- Novel approaches to address HIV prevention and / or treatment and substance use in the context of infectious disease and / or psychiatric comorbidities.
- Applications of optimization and / or adaptive trial strategies to increase delivery of evidence-based practices and improve outcomes, particularly complex patient / client populations.
- Studies developing and testing cutting-edge technologies to deliver HIV and SUD therapeutics to PLWH
- Innovative strategies to optimize immune responses to HIV and HIV vaccine candidates in the presence of substance use
- Creative strategies to monitor HIV infection or latency in the CNS and / or determine the size and nature of the viral reservoir under the influences of substance use and / or therapies for SUD and HIV.
- Research to identify the underlying molecular mechanisms by which HIV latency is initiated, established, and maintained in the CNS, lymphoid and myeloid tissues and how substance use might influence these processes.
- Innovative approaches to achieve sustained ART-free remission and / or eradication of HIV among PWUD who experience ART interruptions and delays, and relapse in drug use.
- Explore and develop potential biomarkers or therapeutic targets to prevent, treat, and / or eliminate CNS HIV reservoirs in people with SUD
- Application of spatial genomics and other related state-of-the art strategies to address questions at the intersection of HIV and SUD
- Novel approaches to unravel the roles of addictive substances in epigenomic or transcriptional regulation, or other molecular processes critical to HIV replication, persistence and reactivation.
- Research to decipher the contributions of addictive substances and inflammatory stimuli on HIV infection, latency or pathogenesis
- In vivo analysis of HIV infection, latency and immunity as a result of addictive substance use using longitudinal patient studies or primate models.
Funding Information
- Funds Available and Anticipated Number of Awards: National Institute on Drug Abuse (NIDA) intends to commit $ 3.5 M in FY 2022, 2023, and 2024 to fund 3-5 awards.
- Award Project Period: The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Eligibility Criteria
- Higher Education Institutions
- Public / State Controlled Institutions of Higher Education
- Private Institutions of Higher Education
- The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
- Hispa nic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
- Nonprofits Other Than Institutions of Higher Education
- Nonprofits with 501 (c) (3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501 (c) (3) IRS Status (Other than Institutions of Higher Education)
- For-Profit Organizations
- Small Businesses
- For-Prof it Organizations (Other than Small Businesses)
- Local Governments
- State governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian / Native American Tribal Governments (Federally Recognized)
- Indian / Native American Tribal Governments (Other than Federally Recognized)
- Federal Governments
- Eligible Agencies of the Federal Government
- US Territory or Possession
- Other
- Independ ent School Districts
- Public Housing Authorities / Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations
- Non-do me stic (non-US) Entities (Foreign Institutions)
For more information, visit https://www.grants.gov/web/grants/view-opportunity.html?oppId=335593